Drug Trial Radar · NCT07318909
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Dec 31, 2027
Primary completion
Dec 31, 2028
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Gritgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, open-label, dose-escalation, exploratory study to evaluate the safety, tolerability, and efficacy of a single administration of GS1168 Injection in Chinese adult phenylketonuria (PKU) with PAH mutation.
Conditions
- Phenylketonuria (PKU)
Interventions
GS1168 injectionDrug
The dose levels are as follows: 1. A single intravenous administration of GS1168 injection at dose level 1; 2. A single intravenous administration of GS1168 injection at dose level 2; 3. A single intravenous administration of GS1168 injection at dose level 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse event (AE), including serious adverse event (SAE) and adverse event of special interest (AESI)Time frame: Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.